| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 05/27/2009 | CN100490845C Herbal composition and its use in chemotheraphy |
| 05/27/2009 | CN100490829C Selenium-rich hedgehog fungus extract preparation for treating colitis, gastritis and stomach cancer and its preparing process |
| 05/27/2009 | CN100490820C Anti-tumor formulations comprising defibrotide alone or in combination with other anti-tumor agents |
| 05/27/2009 | CN100490817C Use of antitumor indolopyrrolocarbazole derivative and other anticancer agent in combination |
| 05/27/2009 | CN100490812C Compisition as substitution of phthalocyanine cooperator and low density lipoprotein and its preparation process |
| 05/27/2009 | CN100490802C Injection use medicine composition containing water-soluble 17-allylamino-17-demethoxy geldanamycin |
| 05/27/2009 | CN100490801C Ginkgolide B dropping pill and its preparing method |
| 05/27/2009 | CN100490794C Lomustine liposome freeze-drying powder injection and its preparation method |
| 05/27/2009 | CN100490791C Compositions and methods to treat neovascularization and disease associated with thereof |
| 05/26/2009 | US7538224 Such as 2,4-dihydroxy-6-(2-methoxyethyl)phenylphenylketone; antitumor activity; heat shock protein (Hsp) suppression |
| 05/26/2009 | US7538220 silyl camptothecin derivatives for cancer and/or leukemia; cytotoxic; DNA-topoisomerase I inhibitors; antitumor agents; 7-trimethylsilyl-10-acetoxy camptothecin, 7-trimethylsilyl-11-fluoro camptothecin |
| 05/26/2009 | US7538216 Guanidino phenylalanin compounds used as urokinase inhibitors |
| 05/26/2009 | US7538215 Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| 05/26/2009 | US7538195 Antibodies that bind to human insulin-like growth factor-I receptor; particularly, antibodies that inhibit the cellular functions of the IGF-I receptor; cancer treatment |
| 05/26/2009 | US7538182 conjugated by bridging molecules to proteins or polypeptides, reporter groups or cytotoxic agents; cancer |
| 05/26/2009 | US7538129 Diazonamide A analog |
| 05/26/2009 | US7538119 Metabolically resistant 41-[13C]methoxyl rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (41-[13C]methoxyl CCI-779); study pharmacokinetics; Rapamycin 31-O-trimethyl silyl ether, 42-ester with 2,2,5-trimethyl[1,3-dioxane]-5-carboxylic acid; treat cancers |
| 05/26/2009 | US7538118 6-aminomorphinane derivatives, method for production and use thereof |
| 05/26/2009 | US7538109 Quinoxalin-3-one derivatives as orexin receptor antagonists |
| 05/26/2009 | US7538100 17α-alkyl-17β-oxy-estratrienes and intermediate products for their production, use of the 17α-alkyl-17β-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations |
| 05/26/2009 | US7538093 Compositions and methods for therapeutic use |
| 05/26/2009 | US7538091 D-retro-inverso amino acid sequence transporter peptide conjugated to nucleic acid biological effector; translocation across the membrane of pancreatic B-cells |
| 05/26/2009 | US7538089 Anti-inflammatory compounds and uses thereof |
| 05/26/2009 | US7537924 Modified herpes simplex viral particle for targeting and destroying tumor cells |
| 05/26/2009 | US7537906 inhibition of Akt activity or inhibition of the survival signalling pathway in which Akt is involved in the cells, akt is a kinase |
| 05/26/2009 | US7537887 Relates to regulation of activity of NET (ERP/SAP-2) protein and to compounds which modify or regulate NET protein activity; methods of screening for agonists or antagonists of NET in order to identify new pro- or anti-angiogenic compounds |
| 05/26/2009 | US7537763 Tumor necrosis factor specific immunoglobulin for use in treatment and prevention of tumor disorder; tissue targeted therapy |
| 05/26/2009 | US7537759 Modulating angiogenesis |
| 05/26/2009 | CA2497857C Novel p-selectin ligand protein |
| 05/26/2009 | CA2474373C N-biphenylmethyl aminocycloalkanecarboxamide derivatives with a substituent on the methyl useful as bradykinin antagonists |
| 05/26/2009 | CA2459432C Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders |
| 05/26/2009 | CA2454675C 17alfa, 21-dihydroxypregnene esters as antiandrogenic agents |
| 05/26/2009 | CA2445478C Retinol derivatives potentiation of active substances by micellar preparation |
| 05/26/2009 | CA2441441C Combination of a taxane and a cyclin-dependent kinase inhibitor |
| 05/26/2009 | CA2429020C Use of cci-779 as an antineoplastic agent |
| 05/26/2009 | CA2403630C Methods for inhibiting angiogenesis and tumor growth |
| 05/26/2009 | CA2393072C Mono- and disaccharide derivatives |
| 05/26/2009 | CA2387201C Tetrahydroquinoline derivatives |
| 05/26/2009 | CA2367017C Inhibitors of impdh enzyme |
| 05/26/2009 | CA2354774C Farnesyl protein transferase inhibitors |
| 05/26/2009 | CA2339495C Phospholipids with unsaturated alkyl and acyl chains |
| 05/26/2009 | CA2298523C Therapeutic process for inhibiting nf-.kappa.b |
| 05/26/2009 | CA2295936C Chimeric interleukin-6 soluble receptor/ligand protein, analogs thereof and uses thereof |
| 05/26/2009 | CA2254420C Substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them |
| 05/26/2009 | CA2230492C Human growth hormone variants |
| 05/26/2009 | CA2226331C Antitumor 2-aminocarbonyl-1,2-bis(methylsulfonyl)-1-(substituted)hydrazines |
| 05/26/2009 | CA2174325C Non-antigenic branched polymer conjugates |
| 05/22/2009 | WO2009065090A2 Pharmaceutical compositions for the treatment of conditions responsive to proteasome inhibition |
| 05/22/2009 | WO2009065028A2 Brca1-based breast or ovarian cancer prevention agents and methods of use |
| 05/22/2009 | WO2009064854A2 Humanized antibodies against tl1a |
| 05/22/2009 | WO2009064835A1 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors |
| 05/22/2009 | WO2009064738A2 Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents |
| 05/22/2009 | WO2009064675A1 Mapk/erk kinase inhibitors |
| 05/22/2009 | WO2009064590A2 Therapeutic applications of p53 isoforms in regenerative medicine, aging and cancer |
| 05/22/2009 | WO2009064486A2 Inhibitors of pim protein kinases, compositions, and methods for treating cancer |
| 05/22/2009 | WO2009064444A2 Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents |
| 05/22/2009 | WO2009064399A1 Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same |
| 05/22/2009 | WO2009064300A1 Combinations of hdac inhibitors and cytokines/growth factors |
| 05/22/2009 | WO2009063998A1 Nucleic acid having hydrophobic substance added thereto, and use thereof |
| 05/22/2009 | WO2009063993A1 Fused pyridine derivative and use thereof |
| 05/22/2009 | WO2009063990A1 Benzazepinone compound |
| 05/22/2009 | WO2009063970A1 Diagnosis and treatment of cancer using anti-gpr49 antibody |
| 05/22/2009 | WO2009063965A1 Monoclonal antibody capable of binding to anexelekto, and use thereof |
| 05/22/2009 | WO2009063576A1 Anticancer agent |
| 05/22/2009 | WO2009063492A2 Novel agents for treatment of ailments and dysfunctions |
| 05/22/2009 | WO2009063461A1 Methods of treating cancer using anti cd24 antibodies |
| 05/22/2009 | WO2009063240A1 2,4-diaminopyrimidine derivatives useful as inhibitors of aurora kinase |
| 05/22/2009 | WO2009063070A2 Quinoline derivatives and their use as tyrosine kinase inhibitors |
| 05/22/2009 | WO2009063054A1 Novel bifunctional compounds which inhibit protein kinases and histone deacetylases |
| 05/22/2009 | WO2009062740A1 Use of an ozone/oxygen mixture as primary anticancer therapy through intraperitoneal insufflation |
| 05/22/2009 | WO2009062690A1 Axl antibodies |
| 05/22/2009 | WO2009062683A1 C-19 steroids for therapeutic uses |
| 05/22/2009 | WO2009062658A1 Methods for identification of jak kinase interacting molecules and for the purification of jak kinases |
| 05/22/2009 | WO2009062399A1 Peptide ligand directed drug delivery |
| 05/22/2009 | WO2009062398A1 Novel thermosensitive liposomes containing therapeutic agents |
| 05/22/2009 | WO2009062344A1 Use of lymphotoxin for sensitizing tumor cells to chemotherapeutic drugs |
| 05/22/2009 | WO2009062342A1 Cephalomannine derivatives and their preparation, medicinal composition and use |
| 05/22/2009 | WO2009062339A1 Methods of using interleukin-1 receptor antagonist as a myeloprotective agent |
| 05/22/2009 | WO2009062258A1 N-containing heterocyclic compounds |
| 05/22/2009 | WO2009043507A3 Use of a peptide as a therapeutic agent |
| 05/22/2009 | WO2009043468A3 Use of corticotropin-releasing factor as a therapeutic agent |
| 05/22/2009 | WO2009040087A3 Therapeutic use of peptide yglf and combination with kvlpvpq |
| 05/22/2009 | WO2009040073A3 Use of a peptide as a therapeutic agent |
| 05/22/2009 | WO2009040032A3 Use of a peptide as a therapeutic agent |
| 05/22/2009 | WO2009040025A3 Use of neuropeptide sf, alone or in combination with glp-2, as a therapeutic agent |
| 05/22/2009 | WO2009039969A3 Use of a vla-4 inhibitor tetrapeptide, alone or in combination with bpp-b, as a therapeutic agent |
| 05/22/2009 | WO2009039397A3 Substituted amides, methods of making, use thereof for the treatment of diseases such as cancer |
| 05/22/2009 | WO2009033822A3 Use of a combination of a cathepsin g fragment and teprotide as a therapeutic agent |
| 05/22/2009 | WO2009033812A3 Use of a combination of neuropeptide-ff and alpha-msh as a therapeutic agent |
| 05/22/2009 | WO2009033800A3 Use of a peptide as a therapeutic agent |
| 05/22/2009 | WO2009033771A3 Use of a peptide as a therapeutic agent |
| 05/22/2009 | WO2009033736A3 Use of met-enkephalin as a therapeutic agent |
| 05/22/2009 | WO2009033735A3 Use of melanin concentrating hormone and met-enkephalin as therapeutic agents |
| 05/22/2009 | WO2009033669A3 Use of the peptide his-ser-leu-gly-lys-trp-leu-gly-his-pro-asp-lys-phe alone or in combination with the peptide pro-gly-thr-cys-glu-ile-cys-ala-tyr-ala-ala-cys-thr-gly-cys-oh as a therapeutic agent |
| 05/22/2009 | WO2009028968A8 Cell marker of melanocyte cell lineage and uses thereof |
| 05/22/2009 | WO2009024820A3 Therapeutic treatment 014 |
| 05/22/2009 | WO2009024542A3 Purin derivatives for use in the treatment of fab-related diseases |
| 05/22/2009 | WO2009016072A3 A morpholinyl anthracycline derivative combined with protein kinase inhibitors |
| 05/22/2009 | WO2009000504A3 Injectable formulation for photodynamic therapy |
| 05/22/2009 | WO2007059329A3 Methods and compositions for treating cancer |